Xenon Pharmaceuticals Inc
XENEStock
$66.98+115.09%52W
Market Cap$6.46B
P/E—
Div yield—
Beta0.63
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)51.30%
Price vs S&P 500 (4W)29.64%
VGM Score32.37
Market Capitalization$6.46B
Earnings Surprise History
Q1 26-1.17est. -1.21
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.38
4.38
4.38
4.38
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
XENEXenon Pharmaceuticals Inc | F | F | B | $66.98 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Xenon Pharmaceuticals is a biopharmaceutical company developing novel treatments for neurological and psychiatric disorders, including epilepsy, depression, and pain. The company's pipeline includes three epilepsy candidates—XEN1101, NBI-921352, and XEN496—as well as oral Nav1.7 inhibitors for pain management. It targets areas with significant unmet medical need in neuroscience.